Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeTopicsGenome EditingAxiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for...
Credit: monsitj / Getty Images/iStockphoto
In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice.
Listed below are links to the
GENstories referenced in this episode of
Touching Base:
StockWatch: Axiom CEO Explains Plans for Hong Kong IPO
By Alex Philippidis,GEN Edge, July 27, 2026
Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate
By Alex Philippidis,GEN Edge, July 30, 2026
, July 29, 2026
Base Editing Strategy Alleviates Huntington’s Disease in Mice
GEN, July 29, 2026
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
The State of Biologics Testing 2026
Charles River Laboratories andGEN, June 10, 2026
Produced with support from:
Also of Interest
Gene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat ModelInhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis ModelsScientists Analyze 267 Receptors That Control Protein Fate in Rare DiseasesGene Switch Uses Electromagnetic Fields to Control Genes RemotelyGenetic Findings Provide Insights Into Leading Cause of Back PainLatigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain CandidateRelated Media
From Functional Genomics to Cell Therapy: The Role of CRISPR-Based Gene EditingWhat’s in Store for 2024? Three CEOs Look Ahead and Look Back on “Close to the Edge”Running Up That Hill: Nessan Bermingham on Close to the EdgeGene Therapy for GSD Administered to First PatientCRISPR-Cas9: The Key to Fighting Genetic Disease?Copyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
